A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples